Weinstock, R. S., Goldberg, R. B., Guyton, J. R., Mazzone, T., Polis, A., Tomassini, J. E., … Tershakovec, A. M. (2007). PO23-777 EFFECT OF EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN ON ATTAINING RECOMMENDED LEVELS OF LDL-C, APOLIOPROTEIN B, NON-HDL-C AND HS-CRP IN TYPE 2 DIABETES. In Atherosclerosis Supplements (Vol. 8, pp. 207–207). Elsevier BV. https://doi.org/10.1016/s1567-5688(07)71787-7

Weinstock, R. S., R. B. Goldberg, J. R. Guyton, T. Mazzone, A. Polis, J. E. Tomassini, E. Desrosiers, and A. M. Tershakovec. “PO23-777 EFFECT OF EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN ON ATTAINING RECOMMENDED LEVELS OF LDL-C, APOLIOPROTEIN B, NON-HDL-C AND HS-CRP IN TYPE 2 DIABETES.” In Atherosclerosis Supplements, 8:207–207. Elsevier BV, 2007. https://doi.org/10.1016/s1567-5688(07)71787-7.

Weinstock RS, Goldberg RB, Guyton JR, Mazzone T, Polis A, Tomassini JE, et al. PO23-777 EFFECT OF EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN ON ATTAINING RECOMMENDED LEVELS OF LDL-C, APOLIOPROTEIN B, NON-HDL-C AND HS-CRP IN TYPE 2 DIABETES. In: Atherosclerosis Supplements. Elsevier BV; 2007. p. 207–207.

Weinstock, R. S., et al. “PO23-777 EFFECT OF EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN ON ATTAINING RECOMMENDED LEVELS OF LDL-C, APOLIOPROTEIN B, NON-HDL-C AND HS-CRP IN TYPE 2 DIABETES.” Atherosclerosis Supplements, vol. 8, no. 1, Elsevier BV, 2007, pp. 207–207. Crossref, doi:10.1016/s1567-5688(07)71787-7.

Weinstock RS, Goldberg RB, Guyton JR, Mazzone T, Polis A, Tomassini JE, Desrosiers E, Tershakovec AM. PO23-777 EFFECT OF EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN ON ATTAINING RECOMMENDED LEVELS OF LDL-C, APOLIOPROTEIN B, NON-HDL-C AND HS-CRP IN TYPE 2 DIABETES. Atherosclerosis Supplements. Elsevier BV; 2007. p. 207–207.